<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02223208</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_PTCL13</org_study_id>
    <nct_id>NCT02223208</nct_id>
  </id_info>
  <brief_title>Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas</brief_title>
  <acronym>FIL_PTCL13</acronym>
  <official_title>Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <brief_summary>
    <textblock>
      This is a multicenter study that includes two phases:

        1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to
           CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose
           escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin
           will be used for the subsequent phase II study.

        2. A phase II study to evaluate the efficacy (response rate, progression free survival and
           overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy
           including SCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) of Ro-CHOEP-21 (Phase I endpoint)</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of dose-limiting toxicity (DLT) of Ro-CHOEP-21, considering as maximum dose the one causing induction of any grade ≥ 3 non hematologic toxicity or a delay &gt;15 days of planned cycle date observed during the first two cycles according to the definitions of NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (2009)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) of Ro-CHOEP-21 (Phase II endpoint)</measure>
    <time_frame>18 months</time_frame>
    <description>PFS on intention to treatment (ITT) evaluated at 18 months. PFS will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching SCT (Phase I endpoint)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients reaching SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR = Overall response rate (Phase I endpoint)</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response rate (ORR, defined according to the Cheson 2007 response criteria) of the combination of Ro-CHOEP-21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) and Complete Response (CR)(Phase II endpoint)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR and CR (defined according to the Cheson 2007 response criteria), after induction treatment and after SCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS) (Phase II endpoint)</measure>
    <time_frame>18 months</time_frame>
    <description>Event free survival (EFS) defined as the time between the date of enrollment and the date of discontinuation of treatment for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase II endpoint)</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival (OS) defined as the time between the date of enrolment and the date of death from any cause in the ITT population enrolled in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) and Overall Survival (OS) (Phase II endpoint)</measure>
    <time_frame>3 months</time_frame>
    <description>PFS and OS in patients not responding to the first 3 courses of Ro-CHOEP-21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities (Phase II endpoint)</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation during the interim analyses of any grade III or higher toxicities, recorded and classified according to the definitions of NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (2009)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Higher toxicities (Phase II endpoint)</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation during all the pretransplant phase of any grade III or higher toxicities, recorded and classified according to the definitions of NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (2009)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality (TRM) (Phase II Endpoint)</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment-related mortality defined as any death that was not attributable to the lymphoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease (GVHD) (Phase II endpoint)</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of acute and chronic GVHD in allografted patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of response biomarkers (eg TET2 mutations)</measure>
    <time_frame>8 years</time_frame>
    <description>Evaluation of response biomarkers (eg TET2 mutations)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Peripheral T-cell Lymphomas (PTCL)</condition>
  <condition>PTCL-NOS</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma (AITL)</condition>
  <condition>ALK- Anaplastic Large Cell Lymphoma (ALCL)</condition>
  <arm_group>
    <arm_group_label>Ro-CHOEP-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ro-CHOEP-21 (PHASE I)</intervention_name>
    <description>Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8
Dose modification according to toxicity:
14mg/ms day +1 and +8
10mg/ms day +1 and +8
8mg/ms day +1 and +8
CHOEP-21
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg orally from days +1 to +5
PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --&gt; AUTO-SCT, PR --&gt; ALLO-SCT)</description>
    <arm_group_label>Ro-CHOEP-21</arm_group_label>
    <other_name>Romidepsin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Vincristin</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ro-CHOEP-21 (PHASE II)</intervention_name>
    <description>Ro-CHOEP-21 x 3 cycles
Romidepsin dose according to phase I iv day +1 and +8
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg orally from days +1 to +5
PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --&gt; AUTO-SCT, PR --&gt; ALLO-SCT)</description>
    <arm_group_label>Ro-CHOEP-21</arm_group_label>
    <other_name>Romidepsin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Vincristin</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 e ≤ 65 years

          2. Peripheral T-cell lymphomas at diagnosis including: PTCL-NOS, AITL, ALK-ALCL

          3. Stage II-IV

          4. Written informed consent

          5. No prior treatment for lymphoma

          6. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by
             lymphoma)

          7. HIV negativity

          8. Absence of active hepatitis C virus (HCV) infection

          9. HBV negativity or patients with HBcAb +, HBsAg -, HBs Ab+/- with HBV-DNA negativity
             (in these patients Lamivudine prophylaxis is mandatory)

         10. Levels of serum bilirubin, alkaline phosphatase and transaminases &lt; 2 the upper normal
             limit, if not disease related

         11. No psychiatric illness that precludes understanding concepts of the trial or signing
             informed consent

         12. Ejection fraction &gt; 50% and myocardial stroke in the last year nor QT prolongation
             (QTc interval &lt; 480 msec using the Fridericia formula)

         13. Clearance of creatinine &gt; 60 ml/min if not disease related

         14. Spirometry Diffusion Capacity (DLCO) &gt; 50%

         15. Absence of active, uncontrolled infection

         16. For males and females of child-bearing potential, agreement upon the use of effective
             contraceptive methods prior to study entry, for the duration of study participation
             and in the following 90 days after discontinuation of study treatment

         17. Availability of histological material for central review and pathobiological studies.

        Exclusion Criteria:

          1. Age &lt;18 e &gt; 65 years

          2. Hystology other than: PTCL-NOS, AITL, ALK-ALCL

          3. Stage I

          4. Prior treatment for lymphoma

          5. Positive serologic markers for human immunodeficiency virus (HIV)

          6. Active hepatitis B virus (HBV) infection

          7. Active hepatitis C virus (HCV) infection

          8. Levels of serum bilirubin, alkaline phosphatase and transaminases &gt; 2 the upper normal
             limit, if not disease related

          9. Ejection fraction &lt; 50% and no myocardial stroke in the last year or QT prolongation
             (QTc interval &gt; 480 msec using the Fridericia formula)

         10. Clearance of creatinine &lt; 60 ml/min if not disease related

         11. Spirometry Diffusion Capacity (DLCO) &lt; 50%

         12. Pregnancy or lactation

         13. Patient not agreeing to take adequate contraceptive measures during the study

         14. Psychiatric disease that precludes understanding concepts of the trial or signing
             informed consent

         15. Any active, uncontrolled infection

         16. Prior history of malignancies other than PTCLs in the last five years (except for
             basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
             or breast).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Corradini, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Findazione IRCCS Istituto Nazionale dei Tumori di Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uffici Studi FIL</last_name>
    <phone>0039 0131206288</phone>
    <email>segreteria@filinf.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
      <phone>0039 0131206133</phone>
      <email>flaviasalvi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Attilio Olivieri, PROF</last_name>
      <phone>0039 0715964226</phone>
      <email>a.olivieri@unipm.it</email>
    </contact>
    <investigator>
      <last_name>Attilio Olivieri, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, PROF</last_name>
      <phone>0039 0805593471</phone>
      <email>giorgina.specchia@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Stefoni, MD</last_name>
      <phone>0039 0516364042</phone>
      <email>vittorio.stefoni2@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Stefoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>26123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Re, MD</last_name>
      <phone>0039 0303995438</phone>
      <email>ematologia@spedalicivili.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Cabras, MD</last_name>
      <phone>0039 0706095171</phone>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione di Ricerca e Cura &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti, MD</last_name>
      <phone>0039 0874312317</phone>
      <email>sstorti@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Storti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S.Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Castellino, MD</last_name>
      <phone>0039 0171641070</phone>
      <email>castellino.c@ospedale.cuneo.it</email>
    </contact>
    <investigator>
      <last_name>Claudia Castellino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerardo Musuraca, MD</last_name>
      <phone>0039 0543739280</phone>
      <email>g.musuraca@irst.em.it</email>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, MD</last_name>
      <phone>0039 0882410566</phone>
      <email>ematologia@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San Martino - Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16321</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Ballerini, PROF</last_name>
      <phone>0039 0105554336</phone>
      <email>ballerini@unige.it</email>
    </contact>
    <investigator>
      <last_name>Filippo Ballerini, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San Martino - UO Ematologia 1</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16321</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Giovanna Congiu, MD</last_name>
      <phone>0039 0105513731</phone>
      <email>angelagiovanna.congiu@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Angela Giovanna Congiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>0039 02 82244080</phone>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Baldini, MD</last_name>
      <phone>0039 02 55033334</phone>
      <email>luca.baldini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Luca Baldini, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS &quot;Istituto Nazionale dei Tumori&quot;</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Corradini, PROF</last_name>
      <phone>0039 0223902950</phone>
      <email>paolo.corradini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Corradini, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Rusconi, MD</last_name>
      <phone>0039 02 64447597</phone>
      <email>chiara.rusconi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Rusconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello)</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Patti, MD</last_name>
      <phone>0039 0917803162</phone>
      <email>kpatti@ospedaliriunitipalermo.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. di Pescara-Ospedale Civile Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli, MD</last_name>
      <phone>0039 0854252838</phone>
      <email>f.angrilli@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Angrilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico (CRO)</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <phone>0039 043459730</phone>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Re, MD</last_name>
      <phone>0039 0521 703962</phone>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Arcaini, MD</last_name>
      <phone>0039 0382501381</phone>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>PZ</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Guariglia, MD</last_name>
      <phone>0039 0972726225</phone>
      <email>robertoguariglia@libero.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Guariglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi - Melacrino - Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
      <phone>0039 0965397653</phone>
      <email>cstelit@libero.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Arcispedale &quot;Santa Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Merli, MD</last_name>
      <phone>0039 0522296618</phone>
      <email>merli.francesco@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Hohaus, MD</last_name>
      <phone>0039 0630154278</phone>
      <email>stephan.hohaus@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalia Molinari, MD</last_name>
      <phone>0039 0541705423</phone>
      <email>annalia.molinari@auslrn.net</email>
    </contact>
    <investigator>
      <last_name>Annalia Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Città della Salute e della Scienza - Ematologia 1U</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <phone>0039 0116334198</phone>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Città della Salute e della Scienza - SC Ematologia</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Chiappella, MD</last_name>
      <phone>0039 0116336751</phone>
      <email>achiappella@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Chiappella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja, MD</last_name>
      <phone>0039 0432559604</phone>
      <email>zaja.francesco@aoud.sanita.fgv.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS 6 - Ospedale S. Bortolo di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Visco, MD</last_name>
      <phone>0039 0444 753573</phone>
      <email>carlovisco@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Visco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Benedetti, MD</last_name>
      <phone>0039 045 8124647</phone>
      <email>fabio.benedetti@univr.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Benedetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Rigacci, MD</last_name>
      <phone>0039 055 7946448</phone>
      <email>luigi.rigacci@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Pinto, MD</last_name>
      <phone>0039 0815903381</phone>
      <email>a.pinto@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università del Piemonte Orientale - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, PROF</last_name>
      <phone>0039 03213732194</phone>
      <email>gaidano@med.unipmn.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. di Perugia - Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Flenghi, MD</last_name>
      <phone>0039 075 5784110</phone>
      <email>flenghi@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Leonardo Flenghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale G. Da Saliceto - AUSL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Arcari, MD</last_name>
      <phone>0039 0523 303719</phone>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani, MD</last_name>
      <phone>0039 0544286223</phone>
      <email>monica.tani@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL</keyword>
  <keyword>PTCL-NOS</keyword>
  <keyword>AITL</keyword>
  <keyword>ALCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

